Compare Twilio Inc (TWLO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twilio Inc vs Twist Bioscience Corp — how do they compare? Twilio Inc trades at $227.45 (market cap $34.69B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twilio Inc is far larger — about 4.1× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| TWLO | TWST | |
|---|---|---|
Market Cap | $34.69B | $8.42B |
Sector | Technology | Health |
52-Week High | $255.95 | $153.10 |
52-Week Low | $100.09 | $24.16 |
Enterprise Value | $33.10B | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twilio (TWLO) trades at $225.89, down 3.04% today, showing strong fundamental momentum with three consecutive quarterly earnings beats and accelerating revenue growth from $3.8B in 2022 to $5.1B in 2025. The company has achieved profitability with a 20.62% net income margin in 2025, reversing previous losses, while technical indicators show a neutral stance with support at $222 and resistance at $230.
The outlook remains positive with 77% analyst buy ratings and a $266.31 consensus price target, representing 18% upside potential. Key risks include execution of AI strategy and competitive pressures in communications infrastructure, but strong free cash flow generation and strategic positioning for AI-driven customer engagement support the bullish case.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
